• Markets
  • icon
  • Companies
IVX · ASX

Invion Ltd. (ASX:IVX)

AU$0.0055

 0.0 (0.0%)
ASX:Live
12/04/2024 12:00:00 AM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

IVX Overview

IVX Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About IVX

Telephone

Address

Description

Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatment for cancers, atherosclerosis, and infectious diseases. The company was founded on October 11, 2000 and is headquartered in Melbourne, Australia.

IVX Price Chart

Key Stats

Market Cap

AU$35.33M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.01

Trade Value (12mth)

AU$1,439.00

1 week

10%

1 month

10%

YTD

10%

1 year

-21.43%

All time high

0.55251

Key Fundamentals

EPS 3 yr Growth

0.000%

EBITDA Margin

-23.50%

Operating Cashflow

-$2m

Free Cash Flow Return

-9.50%

ROIC

-8.50%

Interest Coverage

N/A

Quick Ratio

8.90

Other Data

Shares on Issue (Fully Dilluted)

6422m

HALO Sector

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

IVX Announcements

Latest Announcements

Date Announcements

05 March 24

Presentation at East-West Summit in Singapore

×

Presentation at East-West Summit in Singapore

04 March 24

INV043 With ICI Therapy Achieved 80% Tumour Control For ASCC

×

INV043 With ICI Therapy Achieved 80% Tumour Control For ASCC

28 February 24

Appendix 4D and Half Year Financial Report

×

Appendix 4D and Half Year Financial Report

23 February 24

Agreement with Dr.inB to develop Photosoft treatment for HPV

×

Agreement with Dr.inB to develop Photosoft treatment for HPV

30 January 24

Activities Report and Appendix 4C

×

Activities Report and Appendix 4C

19 January 24

Application for quotation of securities - IVX

×

Application for quotation of securities - IVX

19 January 24

Section 708A Cleansing Statement

×

Section 708A Cleansing Statement

19 January 24

Change of Director's Interest Notice- Robert Merriel

×

Change of Director's Interest Notice- Robert Merriel

16 January 24

Change of Auditor

×

Change of Auditor

29 November 23

AGM Presentation

×

AGM Presentation

29 November 23

Results of Annual General Meeting

×

Results of Annual General Meeting

29 November 23

Notification regarding unquoted securities - IVX

×

Notification regarding unquoted securities - IVX

21 November 23

Major Milestone towards Clinical Trials

×

Major Milestone towards Clinical Trials

30 October 23

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

30 October 23

Notification of cessation of securities - IVX

×

Notification of cessation of securities - IVX

24 October 23

Activities Report and Appendix 4C

×

Activities Report and Appendix 4C

24 October 23

Investor Presentation

×

Investor Presentation

28 September 23

Annual Report to shareholders

×

Annual Report to shareholders

28 September 23

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

25 September 23

Photosoft Territory Expanded to South Korea for Cancer

×

Photosoft Territory Expanded to South Korea for Cancer

31 August 23

Appendix 4E and Preliminary Financial Report

×

Appendix 4E and Preliminary Financial Report

20 July 23

Activities Report and Appendix 4C

×

Activities Report and Appendix 4C

05 July 23

New Australian Patent Granted

×

New Australian Patent Granted

11 May 23

Notification regarding unquoted securities - IVX

×

Notification regarding unquoted securities - IVX

02 May 23

Application for quotation of securities - IVX

×

Application for quotation of securities - IVX

IVX Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -50.0 -33.3 50.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock 0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -218.7 -71.8 17.6 Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.6 -2.0 -7.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -62.3 3,031.7 -36.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 5,526 6,117 6,420 Lock Lock Lock
Basic m Lock Lock Lock Lock 5,526 6,117 6,420 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 2 3 4 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.0 41.3 24.7 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 4 5 5 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -1 -2 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -72.9 -46.7 49.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -55.6 -57.7 -23.5 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -53.2 -47.6 29.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -67.5 -70.5 -40.2 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -1 -2 -2 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -1 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -55.5 -51.1 28.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -63.6 -68.1 -39.3 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock 0 -1 -2 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 7 3 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -7 -3 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 16 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock 0 -1 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 374.1 -365.3 -70.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock 0.2 -0.3 -0.5 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 1 8 4 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 6 20 19 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -1 -8 -4 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 0 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 5 20 18 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 5 20 18 Lock Lock Lock
     Growth % Lock Lock Lock Lock -11.8 308.7 -6.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -26.3 -11.2 -8.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -31.0 -11.4 -8.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -30.8 -19.1 -8.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -29.0 -18.4 -8.5 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock 8.2 -9.1 -9.5 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.8 4.5 4.2 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -21.6 -43.3 -22.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 1.3 18.7 8.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 1.3 18.7 8.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 96.3 98.0 70.9 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock 49.1 -239.8 -278.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 16.5 43.6 4.7 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 10.4 0.4 0.8 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 19.3 6.7 9.7 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.4 0.2 0.2 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.4 0.2 0.2 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -63.6 -68.1 -39.3 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -26.3 -11.2 -8.5 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -26.3 -11.2 -8.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.0 1.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -31.0 -11.4 -8.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -31.0 -11.4 -8.8 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 22.2 8.4 78.1 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 22.2 8.4 78.1 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 22.2 8.4 78.1 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

IVX Shortsell

Frequently Asked Questions

The current share price of Invion Ltd. (IVX:ASX) is AU$0.0055.
The 52-week high share price for Invion Ltd. (IVX:ASX) is AU$0.01.
The 52-week low share price for Invion Ltd. (IVX:ASX)? is AU$0.00.
Invion Ltd. (IVX:ASX) does not pay a dividend.
Invion Ltd. (IVX:ASX) does not pay a dividend.
Invion Ltd. (IVX:ASX) has a franking level of 0%.
Invion Ltd. (IVX:ASX) is classified in the Healthcare.
The current P/E ratio for Invion Ltd. (IVX:ASX) is .